About EyeGate
EyeGate is a company based in Waltham (United States) founded in 1998. EyeGate has raised $44.47 million across 13 funding rounds from investors including Armistice Capital, Emerge Capital Partners and NiXEN. The company has 12 employees as of December 31, 2022. EyeGate has completed 2 acquisitions, including Jade Therapeutics and Panoptes Pharma. EyeGate offers products and services including Drug Catalog, Special Offers, and Loyalty Programs. EyeGate operates in a competitive market with competitors including CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne, among others.
- Headquarter Waltham, United States
- Employees 12 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kiora Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.47 M (USD)
in 13 rounds
-
Latest Funding Round
$10.75 M (USD), Post-IPO
Aug 09, 2021
-
Investors
Armistice Capital
& 8 more
-
Employee Count
12
as on Dec 31, 2022
-
Investments & Acquisitions
Jade Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EyeGate
EyeGate offers a comprehensive portfolio of products and services, including Drug Catalog, Special Offers, and Loyalty Programs.
Platform for purchasing various affordable medications online
Discounted products including bestsellers and weekly deals
Rewards system for repeat purchases and bonuses
People of EyeGate
Unlock access to complete
Unlock access to complete
Funding Insights of EyeGate
EyeGate has successfully raised a total of $44.47M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10.75 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EyeGate
EyeGate has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Armistice Capital, Emerge Capital Partners and NiXEN.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward France by NiXEN.
|
Locked | Locked | Locked | |
|
Comprehensive strategic expertise in healthcare is provided by MEDICIS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for EyeGate
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyeGate
EyeGate has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Jade Therapeutics and Panoptes Pharma.
Investment portfolio details for EyeGate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapies are developed for severe eye diseases.
|
Locked | Locked | 2013 | Locked | |
|
Polymer-based products for ophthalmic drug delivery are developed using iontophoresis.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for EyeGate
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - EyeGate
Detailed financials for EyeGate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyegate Comparisons
Peer comparison for EyeGate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EyeGate
EyeGate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for corneal transplants are developed by CorneaGen.
|
|
| Locked | Locked | Locked |
iPS cell-based technology for corneal endothelium regeneration is developed.
|
|
| Locked | Locked | Locked |
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| Locked | Locked | Locked |
Medical devices using electrical stimulation for health conditions are developed.
|
Detailed competitors of EyeGate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyegate
Complete news archive for EyeGate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeGate
EyeGate was founded in 1998 and raised its 1st funding round 8 years after it was founded.
EyeGate is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
EyeGate is a funded company, having raised a total of $44.47M across 13 funding rounds to date.
As of Dec 31, 2022, the latest employee count at EyeGate is 12.
EyeGate was founded in 1998 as a specialty pharmaceutical company based in Waltham, United States. Operations center on the development and commercialization of therapeutics and drug delivery systems for ocular disorders. The lead candidate, EGP-437, employs a reformulated dexamethasone phosphate delivered via the EyeGate II system. Phase 3 trials are underway for non-infectious anterior uveitis, while proof-of-concept studies address macular edema variants.
EyeGate offers Drug Catalog, Special Offers, and Loyalty Programs.
EyeGate has made 2 acquisitions, including Jade Therapeutics, and Panoptes Pharma.
EyeGate has 9 investors. Key investors include Armistice Capital, Emerge Capital Partners, NiXEN, MEDICIS, and Ventech Solutions.